Obalon Therapeutics, Inc

(NASDAQ:OBLN)

Latest On Obalon Therapeutics, Inc (OBLN):

Date/Time Type Description Signal Details
2021-04-13 00:04 ESTNewsBABA, MARA, NUAN and CVAC among notable premarket gainersN/A
2021-03-14 09:16 ESTFinancialsCompany financials have been released.Neutral
2021-03-13 05:09 ESTNewsObalon Therapeutics EPS misses by $0.11N/A
2021-03-10 16:50 ESTNewsObalon surges in the pre-market adding to twofold rise this yearN/A
2021-02-19 04:17 ESTAnalyst RatingThe Analyst Target Price has increased from $0.75 to $6.15.Buy
2021-01-20 21:48 ESTNewsObalon is up 76% after announcing merger with ReShape LifesciencesN/A
2020-11-26 21:03 ESTFinancialsCompany financials have been released.Neutral
2020-11-08 00:24 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 16:41 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 13:46 ESTNewsObalon Therapeutics EPS misses by $0.13N/A
2020-09-26 13:36 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 05:42 ESTFinancialsCompany financials have been released.Neutral
2020-09-01 16:39 ESTNewsMorgan Stanley reports 5.9% stake in Obalon TherapeuticsN/A
2020-08-14 09:41 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 21:29 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 13:25 ESTFinancialsCompany financials have been released.Neutral
2020-08-01 01:23 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 02:53 ESTNewsObalon Therapeutics EPS misses by $0.24N/A
2020-07-31 01:53 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 17:22 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 05:22 ESTFinancialsCompany financials have been released.Neutral
2020-07-27 13:18 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 17:57 ESTFinancialsCompany financials have been released.Neutral
2020-07-09 09:33 ESTFinancialsCompany financials have been released.Neutral
2020-07-07 21:22 ESTAnalyst RatingThe Analyst Target Price has decreased from $0.9 to $0.75.Neutral
2020-07-01 17:20 ESTFinancialsCompany financials have been released.Neutral
2020-06-26 09:33 ESTFinancialsCompany financials have been released.Neutral
2020-06-24 17:21 ESTFinancialsCompany financials have been released.Neutral
2020-06-22 09:19 ESTEarnings EstimateAn EPS average of -$0.17 is estimated for the quarter ending on September 30, 2020.Buy
2020-06-20 02:24 ESTNewsObalon Therapeutics EPS misses by $0.17, beats on revenueN/A
2020-06-20 02:24 ESTNewsObalon's retail treatment centers to remain shut; delays shipmentsN/A
2020-06-14 05:16 ESTFinancialsCompany financials have been released.Neutral
2020-06-12 05:38 ESTFinancialsCompany financials have been released.Neutral
2020-06-02 09:18 ESTAnalyst RatingThe Analyst Target Price has decreased from $2.45 to $0.9.Sell
2020-05-27 05:45 ESTFinancialsCompany financials have been released.Neutral
2020-05-06 05:51 ESTFinancialsCompany financials have been released.Neutral
2020-05-01 05:21 ESTFinancialsCompany financials have been released.Neutral
2020-04-12 06:19 ESTNewsObalon Therapeutics EPS misses by $0.09, beats on revenueN/A
2020-04-12 06:19 ESTNewsObalon Therapeutics down 13% premarket on Q4 resultsN/A
2020-04-03 21:20 ESTFinancialsCompany financials have been released.Neutral
2020-04-03 21:20 ESTAnalyst RatingThe Analyst Target Price has decreased from $5.2 to $2.45.Neutral
2020-03-08 00:07 ESTFinancialsCompany financials have been released.Neutral
2020-03-02 04:15 ESTAnalyst RatingThe Analyst Target Price has decreased from $6 to $5.2.Neutral
2020-03-01 00:17 ESTFinancialsCompany financials have been released.Neutral
2020-02-29 17:21 ESTNewsObalon Therapeutics, Inc. (OBLN) CEO Bill Plovanic on Q4 2019 Results - Earnings Call TranscriptN/A
2020-02-28 04:36 ESTFinancialsCompany financials have been released.Neutral
2020-02-28 04:36 ESTEarningsEarnings have been released on February 27, 2020, with -$0.64 earnings per share.Sell
2020-02-28 04:36 ESTEarnings EstimateAn EPS average of -$1.12 is estimated for the 2021 year.Sell
2020-02-28 04:36 ESTEarnings EstimateAn EPS average of -$0.46 is estimated for the quarter ending on June 30, 2020.Buy
2020-02-27 21:54 ESTFinancialsCompany financials have been released.Neutral

About Obalon Therapeutics, Inc (OBLN):

Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California.

OBLN Quotes by TradingView

See Advanced Chart

General

  • Name Obalon Therapeutics, Inc
  • Symbol OBLN
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryMedical Devices
  • Full Time Employees 2
  • Last Split Factor1:10
  • Last Split Date2019-07-25
  • Fiscal Year EndDecember
  • IPO Date2016-10-06
  • Gic SectorHealth Care
  • Gic GroupHealth Care Equipment & Services
  • Gic IndustryHealth Care Equipment & Supplies
  • Gic SubIndustryHealth Care Equipment
  • Web URLhttp://www.obalon.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 12.69
  • Price/Book (Most Recent Quarter) 4.99
  • Enterprise Value Revenue 20.67
  • Enterprise Value EBITDA 0.12
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.27
  • Operating Margin -711%
  • Return on Assets -46%
  • Return on Equity -120%
  • Revenue 1.59 million
  • Earnings Per Share -$13.27
  • Revenue Per Share $0.21
  • Gross Profit 531000
  • Quarterly Earnings Growth -92.2%
View More

Highlights

  • Market Capitalization 37.27 million
  • EBITDA -28148000
  • PE Ratio -2.72
  • Analyst Target Price $6.15
  • Book Value Per Share $0.60
View More

Share Statistics

  • Shares Outstanding 10.02 million
  • Shares Float 7.79 million
  • % Held by Insiders 392%
  • % Held by Institutions 44.31%
  • Shares Short 334623
  • Shares Short Prior Month 442999
  • Short Ratio 0.23
  • Short % of Float 5%
  • Short % of Shares Outstanding 4%
View More

Technicals

  • Beta -1.18
  • 52 Week High $7.57
  • 52 Week Low $0.62
  • 50 Day Moving Average 4.04
  • 200 Day Moving Average 2.03
View More

Dividends

  • Dividend Date 2019-07-25
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Obalon Therapeutics, Inc (OBLN) Dividend Calendar:

OBLN's last dividend payment was made to shareholders on July 25, 2019.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Obalon Therapeutics, Inc (OBLN) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-15$61000-$0.17-$0.06-183.33%
2020-09-302020-11-06$N/A-$0.20-$0.07-185.71%
2020-06-302020-07-30$N/A-$0.54-$0.30-80%
2020-03-312020-06-19$N/A-$0.68-$0.51-33.33%
2019-12-312020-02-27$787000-$0.64-$0.55-16.36%
2019-09-302019-11-08$333000-$6.10-$5.70-7.02%
2019-06-302019-07-24$386000-$2.50-$1.95-28.21%
2019-03-312019-05-10$1.78 million-$3.60-$3.33-8.27%
2018-12-312019-02-22$2.04 million-$3.90-$3.22-21.12%
2018-09-302018-11-02$2.99 million-$3.50-$4.6224.24%
2018-06-302018-08-02$2.73 million-$5.70-$4.93-15.54%
2018-03-312018-05-10$1.35 million-$7.10-$5.03-41.29%
2017-12-312018-03-05$3.69 million-$6.00-$4.55-31.87%
2017-09-302017-11-03$2.79 million-$5.50-$4.56-20.72%
2017-06-302017-08-02$1.96 million-$4.60-$4.57-0.62%
2017-03-312017-05-10$1.47 million-$4.70-$4.720.5%
2016-12-312017-02-23$772000-$5.10-$3.53-44.59%
2016-09-302016-11-10$773000-$54.60-$20.94-160.7%

Obalon Therapeutics, Inc (OBLN) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 157000 N/A N/A N/A 1.49 million
Income Before Tax -1.33 million N/A N/A N/A -4.91 million
Selling General Administrative 1.23 million N/A N/A N/A 3.64 million
Gross Profit 62000 N/A N/A N/A 160000
Ebit -1.33 million N/A N/A N/A -4.98 million
Operating Income -1.33 million N/A N/A N/A -4.98 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue 61000 N/A N/A N/A 787000
Cost of Revenue -1000 N/A N/A N/A 627000
Total Other Income Expense Net N/A N/A N/A N/A 62000
Net Income From Continuing Operations -1.33 million N/A N/A N/A -4.91 million
Net Income Applicable to Common Shares -1.33 million -1.56 million -4.19 million -5.26 million -4.91 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A -326000 N/A N/A
Change to Liabilities -458000 -357000 460000 322000 -570000
Total Cash Flow from Investing Activities N/A 209000 -326000 -150000 -24000
Net Borrowings N/A 430000 N/A N/A -5 million
Total Cash Flow from Financial Activities N/A N/A N/A -296000 9.88 million
Change to Operating Activities 205000 -271000 -206000 -1.29 million -874000
Change in Cash N/A N/A -5.14 million -5.33 million 5.87 million
Total Cash from Operating Activities -1.29 million -2.75 million -4.81 million -4.88 million -3.99 million
Depreciation N/A N/A 225000 232000 220000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A -326000 129000 40000
Change to Account Receivables N/A N/A -176000 -47000 209000
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income 311000 1.6 million 470000 683000 692000
Capital Expenditures N/A N/A 326000 150000 24000
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 5.95 million N/A N/A 8.16 million 4.54 million
Total Stockholder Equity 4.67 million N/A N/A 11.07 million 15.85 million
Other Current Liabilities 4.37 million 3.7 million N/A N/A 1.95 million
Total Assets 10.62 million N/A N/A 19.23 million 20.39 million
Common Stock 8000 8000 8000 8000 8000
Other Current Assets 3.93 million 3.53 million N/A 101000 1.96 million
Retained Earnings -184.8 million -183.44 million -181.88 million -177.69 million -172.43 million
Other Liabilities N/A 7000 N/A N/A N/A
Other Assets N/A 1.3 million 1.3 million N/A N/A
Cash 3.91 million N/A N/A 8.92 million 14.06 million
Total Current Liabilities 5.05 million 5.05 million N/A 7.19 million 3.98 million
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment 957000 1.63 million 1.8 million 3.66 million 2.16 million
Total Current Assets 7.84 million 9.03 million N/A 15.57 million 18.24 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 4.67 million 5.92 million 7.18 million 11.07 million 15.85 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt 430000 N/A N/A N/A N/A
Inventory N/A N/A N/A 1.41 million 1.94 million
Accounts Payable 680000 656000 N/A 1.07 million 648000

Obalon Therapeutics, Inc (OBLN) Chart:

Obalon Therapeutics, Inc (OBLN) News:

Below you will find a list of latest news for Obalon Therapeutics, Inc (OBLN) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Obalon Therapeutics, Inc (OBLN) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Obalon Therapeutics, Inc (OBLN) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757020000043/0001427570-20-000043-index.htm
2019-07-16UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1427570/000000000019011166/0000000000-19-011166-index.htm
2019-08-01UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1427570/000000000019011928/0000000000-19-011928-index.htm
2020-02-14UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1427570/000000000020001427/0000000000-20-001427-index.htm
2020-08-31SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1427570/000089542120000476/0000895421-20-000476-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000089924319021334/0000899243-19-021334-index.htm
2019-08-06SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1427570/000090266419003227/0000902664-19-003227-index.htm
2020-01-23SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1427570/000090266420000410/0000902664-20-000410-index.htm
2019-07-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000090445419000580/0000904454-19-000580-index.htm
2019-08-08SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1427570/000090445419000598/0000904454-19-000598-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000090445419000600/0000904454-19-000600-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000090445419000602/0000904454-19-000602-index.htm
2020-10-23SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1427570/000090445420000667/0000904454-20-000667-index.htm
2020-09-25SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1427570/000091957420006030/0000919574-20-006030-index.htm
2019-02-15SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1427570/000109544919000009/0001095449-19-000009-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1427570/000109544920000020/0001095449-20-000020-index.htm
2019-08-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1427570/000119312519216514/0001193125-19-216514-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1427570/000119312520036613/0001193125-20-036613-index.htm
2019-06-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919004034/0001214659-19-004034-index.htm
2019-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919004035/0001214659-19-004035-index.htm
2019-07-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919004749/0001214659-19-004749-index.htm
2019-07-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919004750/0001214659-19-004750-index.htm
2019-07-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919004751/0001214659-19-004751-index.htm
2019-07-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919004753/0001214659-19-004753-index.htm
2019-07-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919004754/0001214659-19-004754-index.htm
2019-07-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919004755/0001214659-19-004755-index.htm
2019-07-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919004756/0001214659-19-004756-index.htm
2019-07-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919004757/0001214659-19-004757-index.htm
2019-07-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919004758/0001214659-19-004758-index.htm
2019-07-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919004759/0001214659-19-004759-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919005085/0001214659-19-005085-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919005086/0001214659-19-005086-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919005087/0001214659-19-005087-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919005088/0001214659-19-005088-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919005089/0001214659-19-005089-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919005090/0001214659-19-005090-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919005091/0001214659-19-005091-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919005092/0001214659-19-005092-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919006665/0001214659-19-006665-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919006666/0001214659-19-006666-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919006667/0001214659-19-006667-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919006668/0001214659-19-006668-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919006669/0001214659-19-006669-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919006670/0001214659-19-006670-index.htm
2019-11-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465919007137/0001214659-19-007137-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465920000639/0001214659-20-000639-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465920000640/0001214659-20-000640-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465920000641/0001214659-20-000641-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465920000642/0001214659-20-000642-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465920000643/0001214659-20-000643-index.htm
2020-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465920005893/0001214659-20-005893-index.htm
2020-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465920005894/0001214659-20-005894-index.htm
2020-09-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465920007965/0001214659-20-007965-index.htm
2020-09-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465920007966/0001214659-20-007966-index.htm
2020-09-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465920007967/0001214659-20-007967-index.htm
2020-09-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465920007968/0001214659-20-007968-index.htm
2020-09-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465920007969/0001214659-20-007969-index.htm
2020-09-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427570/000121465920007970/0001214659-20-007970-index.htm
2019-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000014/0001427570-19-000014-index.htm
2019-02-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000017/0001427570-19-000017-index.htm
2019-02-2210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1427570/000142757019000019/0001427570-19-000019-index.htm
2019-02-22424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1427570/000142757019000022/0001427570-19-000022-index.htm
2019-04-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000026/0001427570-19-000026-index.htm
2019-04-3010-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1427570/000142757019000030/0001427570-19-000030-index.htm
2019-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1427570/000142757019000033/0001427570-19-000033-index.htm
2019-05-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000035/0001427570-19-000035-index.htm
2019-05-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000038/0001427570-19-000038-index.htm
2019-05-28424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1427570/000142757019000041/0001427570-19-000041-index.htm
2019-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000043/0001427570-19-000043-index.htm
2019-05-308-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000045/0001427570-19-000045-index.htm
2019-05-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000047/0001427570-19-000047-index.htm
2019-05-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000049/0001427570-19-000049-index.htm
2019-05-31PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000051/0001427570-19-000051-index.htm
2019-06-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1427570/000142757019000053/0001427570-19-000053-index.htm
2019-06-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000055/0001427570-19-000055-index.htm
2019-06-13DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000059/0001427570-19-000059-index.htm
2019-06-13DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000060/0001427570-19-000060-index.htm
2019-06-21S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1427570/000142757019000065/0001427570-19-000065-index.htm
2019-06-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000067/0001427570-19-000067-index.htm
2019-06-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000069/0001427570-19-000069-index.htm
2019-07-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000071/0001427570-19-000071-index.htm
2019-07-17CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000073/0001427570-19-000073-index.htm
2019-07-22S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000076/0001427570-19-000076-index.htm
2019-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000082/0001427570-19-000082-index.htm
2019-07-2410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1427570/000142757019000083/0001427570-19-000083-index.htm
2019-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000084/0001427570-19-000084-index.htm
2019-07-26S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1427570/000142757019000088/0001427570-19-000088-index.htm
2019-07-26FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000090/0001427570-19-000090-index.htm
2019-07-30S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1427570/000142757019000097/0001427570-19-000097-index.htm
2019-07-30CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000098/0001427570-19-000098-index.htm
2019-07-30CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000099/0001427570-19-000099-index.htm
2019-08-01CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000102/0001427570-19-000102-index.htm
2019-08-01S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1427570/000142757019000104/0001427570-19-000104-index.htm
2019-08-05424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1427570/000142757019000107/0001427570-19-000107-index.htm
2019-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000110/0001427570-19-000110-index.htm
2019-10-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000112/0001427570-19-000112-index.htm
2019-10-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000114/0001427570-19-000114-index.htm
2019-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757019000119/0001427570-19-000119-index.htm
2019-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1427570/000142757019000120/0001427570-19-000120-index.htm
2020-01-10S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1427570/000142757020000004/0001427570-20-000004-index.htm
2020-01-24S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1427570/000142757020000006/0001427570-20-000006-index.htm
2020-02-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757020000009/0001427570-20-000009-index.htm
2020-02-07S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1427570/000142757020000011/0001427570-20-000011-index.htm
2020-02-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757020000015/0001427570-20-000015-index.htm
2020-02-2710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1427570/000142757020000018/0001427570-20-000018-index.htm
2020-02-27CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1427570/000142757020000022/0001427570-20-000022-index.htm
2020-02-28424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1427570/000142757020000024/0001427570-20-000024-index.htm
2020-03-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757020000026/0001427570-20-000026-index.htm
2020-04-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757020000028/0001427570-20-000028-index.htm
2020-04-2910-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1427570/000142757020000031/0001427570-20-000031-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757020000033/0001427570-20-000033-index.htm
2020-06-1910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1427570/000142757020000035/0001427570-20-000035-index.htm
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757020000037/0001427570-20-000037-index.htm
2020-06-2410-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1427570/000142757020000039/0001427570-20-000039-index.htm
2020-06-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757020000041/0001427570-20-000041-index.htm
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757020000043/0001427570-20-000043-index.htm
2020-07-3010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1427570/000142757020000047/0001427570-20-000047-index.htm
2020-07-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757020000048/0001427570-20-000048-index.htm
2020-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757020000050/0001427570-20-000050-index.htm
2020-08-10DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1427570/000142757020000051/0001427570-20-000051-index.htm
2020-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757020000054/0001427570-20-000054-index.htm
2020-09-01DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1427570/000142757020000057/0001427570-20-000057-index.htm
2020-09-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757020000059/0001427570-20-000059-index.htm
2020-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1427570/000142757020000062/0001427570-20-000062-index.htm
2020-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427570/000142757020000063/0001427570-20-000063-index.htm
2019-08-06SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1427570/000153561019000093/0001535610-19-000093-index.htm
2020-01-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1427570/000153561020000029/0001535610-20-000029-index.htm
2019-03-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1427570/000162828019002886/0001628280-19-002886-index.htm
2019-08-01EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1427570/999999999519001784/9999999995-19-001784-index.htm
2020-02-28EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1427570/999999999520000445/9999999995-20-000445-index.htm

Obalon Therapeutics, Inc (OBLN) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Obalon Therapeutics, Inc (OBLN). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 392%
Institutional Ownership: 4431%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-07-23RAYMOND V DITTAMOREDirectorBuy78,125.00105,597.00https://www.sec.gov/Archives/edgar/data/1427570/000121465919004756/0001214659-19-004756-index.htm
2019-07-23Sharon StevensonDirectorBuy78,125.00105,597.00https://www.sec.gov/Archives/edgar/data/1427570/000121465919004755/0001214659-19-004755-index.htm
2019-11-12William J. PlovanicPresident & CEOBuy65,000.001.66107,822.00106,806.00https://www.sec.gov/Archives/edgar/data/1427570/000121465919007137/0001214659-19-007137-index.htm
2019-08-06Amy VandenBergChief Clinical & Reg OfficerBuy2,500.004.0010,000.0011,764.00https://www.sec.gov/Archives/edgar/data/1427570/000121465919005087/0001214659-19-005087-index.htm
2019-07-23LESLEY H HOWEDirectorBuy78,125.00131,459.00https://www.sec.gov/Archives/edgar/data/1427570/000121465919004758/0001214659-19-004758-index.htm
2019-07-23Kim P. KamdarDirectorBuy78,125.00146,470.00https://www.sec.gov/Archives/edgar/data/1427570/000090445419000580/0000904454-19-000580-index.htm
2019-08-06Nooshin HussainyVP of FinanceBuy5,000.004.0020,000.0016,340.00https://www.sec.gov/Archives/edgar/data/1427570/000121465919005090/0001214659-19-005090-index.htm
2019-08-06Sharon StevensonDirectorBuy7,500.004.0030,000.0018,061.00https://www.sec.gov/Archives/edgar/data/1427570/000121465919005085/0001214659-19-005085-index.htm
2019-08-06LESLEY H HOWEDirectorBuy6,250.004.0025,000.0019,397.00https://www.sec.gov/Archives/edgar/data/1427570/000121465919005086/0001214659-19-005086-index.htm
2019-08-06Kim P. KamdarDirectorBuy12,500.004.0050,000.0027,148.00https://www.sec.gov/Archives/edgar/data/1427570/000090445419000602/0000904454-19-000602-index.htm
2019-08-06PARTNERS X LP INTERWEST10% Share HolderBuy25,000.004.00100,000.00380,224.00https://www.sec.gov/Archives/edgar/data/1427570/000089924319021334/0000899243-19-021334-index.htm
2019-08-06Mark BristerChief Technology OfficerBuy5,000.004.0020,000.0038,865.00https://www.sec.gov/Archives/edgar/data/1427570/000121465919005092/0001214659-19-005092-index.htm
2019-08-06William J. PlovanicPresident & CFOBuy12,500.004.0050,000.0041,806.00https://www.sec.gov/Archives/edgar/data/1427570/000121465919005088/0001214659-19-005088-index.htm
2019-08-06Robert J MacDonaldChief Retail OfficerBuy5,000.004.0020,000.005,245.00https://www.sec.gov/Archives/edgar/data/1427570/000121465919005091/0001214659-19-005091-index.htm
2019-08-06Andrew P RasdalExec Chairman of the BoardBuy12,500.004.0050,000.0077,892.00https://www.sec.gov/Archives/edgar/data/1427570/000121465919005089/0001214659-19-005089-index.htm
2019-07-23Douglas FisherDirectorBuy78,125.0078,125.00https://www.sec.gov/Archives/edgar/data/1427570/000121465919004757/0001214659-19-004757-index.htm
2019-08-06PARTERS VII L P DOMAIN10% Share HolderBuy250,000.004.001,000,000.00813,433.00https://www.sec.gov/Archives/edgar/data/1427570/000090445419000600/0000904454-19-000600-index.htm
2019-07-23DAVID MOATAZEDIDirectorBuy78,125.0083,619.00https://www.sec.gov/Archives/edgar/data/1427570/000121465919004759/0001214659-19-004759-index.htm